Malignant News and Research

RSS

Chink in cancer's armor

Much as the famed starship Enterprise would deploy a deflector shield to evade enemy attack, tumor cells are capable of switching on a molecular force field of their own to fend off treatments aimed at killing them. Now University of Florida researchers have found a chink in their armor.

13 Feb 2006

Nod1 found to control tumor growth in certain breast cancers

This protein was previously thought to play a role solely in the innate immune system's response to bacterial infection. In the new study, which will be published on-line by the Proceedings of the National Academy of Sciences

12 Feb 2006

New report on asbestos litigation trend

The American Academy of Actuaries' Mass Torts Subcommittee have released a report, Current Issues in Asbestos Litigation, examining recent trends in asbestos litigation. Included is a brief overview of asbestos litigation and highlights of recent changes in the litigation environment.

7 Feb 2006

miRNA emerge as a class of gene regulators

Scientists have discovered that a wide variety of different cancers actually share something in common - a molecular "signature" made up of tiny bits of genetic material called microRNA (miRNA) that target key cancer genes and promote malignant growth.

7 Feb 2006

DNA end caps may lead to cancer treatments

The two ends of human DNA have different structures that are treated differently as a cell divides, UT Southwestern Medical Center researchers have found in a study that could help lead to cancer therapies.

7 Feb 2006

American Academy of Dermatology disagrees with eczema medication action taken by FDA

The American Academy of Dermatology (Academy) has issued a statement in response to the U.S. Food and Drug Administration’s (FDA) announcement that a black box warning will be added to the labeling and a medication guide will be distributed for the topical calcineurin inhibitors (TCIs), pimecrolimus and tacrolimus.

23 Jan 2006

Bexarotene shows promise in cancer treatment.

Researchers at Washington University School of Medicine in St. Louis now report that a compound related to vitamin A shows promise in preventing or slowing tumor growth in mice prone to lung cancer. The compound, called bexarotene, doesn't cause the severe skin irritations that have limited the use of other vitamin A derivatives in cancer therapies.

18 Jan 2006

Asbestos: the iron grip of latency

It happens every day somewhere in Europe: a building from the 1950s is demolished. A few children on their way back from school watch the giant bulldozer at work. The engine has already attacked the ground floor - apparently nobody has noticed the asbestos pads…

10 Jan 2006

Thalomid gives hope for blood cancer sufferers

Drug company Celgene says it has halted a pivotal-stage trial of its Thalomid drug earlier than expected after the drug was shown to dramatically limit the progress of the blood cancer multiple myeloma.

9 Jan 2006

Intraperitoneal chemotherapy prolongs survival for women with advanced ovarian cancer

A study featured in this month's edition of Gynecologic Oncology examines the challenges associated with the administration of intra-abdominal chemotherapy, also known as intraperitoneal (IP) chemotherapy.

8 Jan 2006

alphaB-crystallin may be a useful molecular marker to identify women with aggressive breast cancer

A groundbreaking study led by Northwestern University researchers has demonstrated that a protein called alphaB-crystallin, which normally protects cells from stress damage, triggers events that may cause breast cancer when overactive.

6 Jan 2006

Targeted cancer therapies: Another step forward

While it is clear that the treatment of cancer has already begun to undergo a paradigm shift with the inclusion of innovative targeted therapies into current regimens, it would be wrong to assume these products will entirely replace traditional chemotherapy as the standard treatment for cancer sufferers.

22 Dec 2005

Targeted cancer therapies: Another step forward

22 Dec 2005

The role of genes in the development of non-Hodgkin's lymphomas

An international consortium of epidemilogists - including Dr. Alexandra Nieters and Professor Nikolaus Becker of the Clinical Epidemiology Division of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) - has conducted the first ever investigation of genetic factors in the development of non-Hodgkin’s lymphoma (NHL) in a study called InterLymph.

15 Dec 2005

Researchers discover potential mechanism for tumor growth

Researchers at Columbia University Medical Center have identified an inherent feature of stem and progenitor cells that may promote initiation and progression of cancerous tumors.

15 Dec 2005

Important skin color gene identified

With help from a common aquarium pet and a recently released online database of human genetic variation, a collaborative team of Penn State researchers has found what could be the most important skin color gene identified to date.

15 Dec 2005

Hydrogels to potentially make chemotherapy and tissue regeneration more convenient and safe

Scientists at the Institute of Bioengineering and Nanotechnology (IBN) have invented an injectable and biodegradable gel that can deliver drugs at targeted sites or act as a scaffold for tissue repair.

15 Dec 2005

Study suggests a way to eliminate glioblastoma

Scientists have devised a strategy to treat tumors by selectively targeting and killing the malignant cells. A new preclinical study, published in the open access journal PLoS Medicine, has applied the approach to combat glioblastoma multiforme (GBM).

7 Dec 2005

Stem cells may cause some forms of bone cancer

The researchers are the first to identify a population of cells with characteristics of adult and embryonic stem cells in cultures derived from biopsies of patients' bone tumors. They describe their findings in the medical journal Neoplasia.

7 Dec 2005

Cancer cell resistance to chemotherapy drugs - mechanism discovered

Technion-Israel Institute of Technology researchers have discovered new mechanisms developed by cancer cells to become resistant to various chemotherapy drugs.

6 Dec 2005